Objective: To compare medication adherence, pulmonary exacerbations, healthcare utilization, and costs for patients with cystic fibrosis (CF) who utilized a pharmacybased therapy management program to a matched control group. We hypothesized that patient management services would be associated with better medication adherence, and thus require fewer visits to the emergency room or hospitalizations. Propensity score matching and multivariable regression techniques were used to compare outcomes in program participants to matched controls.
surprisingly, poor adherence also was associated with higher healthcare costs, ranging from $8000 to $14 000 more annually, compared to patients with high adherence. 3 However, at least one study found that adherence was associated with length of hospital stay but not exacerbations or costs. 4 Given the high treatment burden for cystic fibrosis, it is not surprising that medication adherence among patients with CF is generally low. 2,4-10 A recent study reported an average claims-based composite medication possession ratio (CMPR) to several long-term pulmonary medications to be 48%, and only 20% of CF patients had a CMPR of at least 80%. 3 Published adherence rates vary greatly by measurement methodology, drug class, and patient characteristics.
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Self-reported rates were generally higher compared to claims-based or electronic monitoring rates. 12 Although barriers to adherence change over a patient's lifetime, 5 ,11 lack of time is often a primary reason cited for nonadherence. 6, 11, 13 Medication adherence was found to be higher for medications that are perceived to have more immediate health benefits (eg, digestive and respiratory drugs) than for more distal benefits (eg, physiotherapy and nutritional supplements). 5, 14 Other factors associated with non-adherence were age and seasonality. 4, 10, 11 Although some studies did not find financial barriers to adherence, 15 new, more expensive treatment options, such as ivacaftor, may increase issues of financial barriers. 16, 17 In a study assessing pediatric patients' utilization of their high-frequency chest wall oscillation device, adherence was significantly impacted by patients' socioeconomic status. 18 In 2017, Zobell et al 2 published the first study to demonstrate a positive impact of pharmacy services on medication adherence for CF patients. This study found significantly higher adherence to dornase alfa after initiation of an integrated pharmacy team model and dedicated CF clinic pharmacist compared to before the interventions. This study was limited to a small sample of pediatric patients in a single health system in one state and calculated adherence for one only medication. Certainly, more research is needed to understand the types of interventions that can decrease treatment barriers and improve adherence. 3 warehouse that contains information derived from more than nine billion medical events generated by more than 140 million unique To be eligible for the study, a patient had to satisfy all of the following inclusion criteria: 2. Aged 6+ (Age was calculated at index date).
3. ≥2 medical claims with a diagnoses for CF (ICD-9 CM Code: 277.0X) occurring ≥30 days apart between December 1, 2013 and March 31, 2016 (ie, the "study period").
4.
Continuously enrolled in the same health plan with both medical and pharmacy benefits 12 months prior to (ie, "baseline period") and 12 months after (ie, "evaluation period") the index date.
Patients were excluded from the study if they received services anytime during the study period from the specialty pharmacy, but had never enrolled in the CC-CF clinical program.
The dependent variables were categorized into four types: (a) medication adherence; (b) healthcare utilization; (c) pulmonary exacerbations; and (d) healthcare costs:
a. Medication adherence rates were calculated as proportion of days covered (PDC) for four CF medications that would qualify a patient for the therapy management program during the study period (ie, tobramycin, aztreonam, ivacaftor, and dornase alfa). For cycled medication, calculations were adjusted as described in Quittner et al. 3 PDC was also converted to a dichotomous variable: low (<0.80) or high (≥0.80), as 80% is a common cut-point in the medication adherence literature and to better compare to Quittner et al. 
| RESULTS
Of the 236 intervention and 724 control patients meeting selection criteria, 202 were propensity score matched from each cohort. Overall, program participants and the comparison group were similar in most characteristics. Among the four utilization outcomes (see Table 3 Pulmonary exacerbations as measured by the proxy of the proportion of patients with hospitalizations with IV antibiotics was lower among the intervention group than controls, though not statistically significant (17% vs 21%, P = 0.19; see Table 3 ).
Adjusted mean costs did not differ significantly for overall medical, Hence, the majority of the pharmacy cost difference can be attributed to the difference in medication adherence.
| DISCUSSION
This study implemented the same selection and exclusion criteria for CF patient identification as Quittner et al 3 and had similar outcome measures, but utilized a different claims source, applied a different research design, and included ivacaftor therapy. Given the genetic influence to this rare disease condition, one would expect some similar results with respect to Quittner et al, 3 but differences were also present.
Higher adherence levels were obtained in this study than the medications common to Quittner et al. 3 Mean PDC levels for tobramycin and dornase alfa in our study cohort (63%) were more similar to values reported for the 13-21 years old cohort in Shakkottai et al 11 (66.7%, tobramycin; 64.7%, dornase alfa). Both variation of adherence by age and variation of age distribution by study may be contributing toward variation of adherence rate by study. 3, 11 In this research, the highest adherence level was for the new medication ivacaftor (n = 17), and the 12% difference to the control cohort (n = 15)
was not significant likely due to the small matched count. High adherence to ivacaftor and low adherence to other CF treatments is consistent with findings from the recent literature review by Narayanan et al. 10 Hospitalizations and outpatient visit rates were rather similar across cohorts in this study, but were about half the rates noted in
Quittner el al. 3 Recently, an analysis of the Cystic Pulmonary exacerbations are rather common in CF and treated with IV antibiotics. [22] [23] [24] In this study, the intervention cohort had a relatively low proportion of patients with such exacerbations compared to the control cohort. The recent VanDevanter et al 22 study on a sample of registry patients determined this event was most associated with a similar event in the prior year compared to 65 other covariates, suggesting a phenotypic expression for some patients.
Hence, unmatched patient mix influences across cohorts may have produced the noted trend.
Finally, while our patient characteristics were similar in age, gender, and CCI level to Quittner et al, 3 our annual healthcare costs were lower ($8.5-$10.4 K vs $34.4-$54.1 K). This differential is likely due to various factors, including insurance mix and our cost imputation method being based on Medicare payment schedules (which would be lower than typical private payer costs found in Quittner et al, but was used to reduce bias for between-group comparisons in our study). 25 Limitations in this study include its observational design, a relatively small matched sample size, reliance on administrative claims, and a high variance for economic outcomes. Given the reliance on medical and pharmacy claims, we could not account for various clinical factors, such as genotype or disease severity. However, patients were matched on several characteristics to account for differences in severity of illness (eg, previous history of diabetes and depression/ anxiety, Charlson comorbidity index, baseline evidence of hospitalization) and the propensity score matched results indicated comparable propensity score distributions across cohorts. Hence, several potential threats to validity were addressed in using this type of propensity score matching to compare cohorts. The rate of hospitalization, while not statistically significant, was higher in the control group, so adherence for hospitalized patients may be underreported due to medications given as an inpatient. However, both average length of stay and the proportion of patients with a hospitalization with IV antibiotics were similar between groups (both P > 0.10). Given the observation period of our study, we were able to assess adherence to ivacaftor but not the lumacaftor/ivacaftor combination therapy.
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A pharmacy-based therapy management program for CF patients was associated with higher adherence to inhaled tobramycin and lower ER rates. Relative to the control cohort, program patients had 21%
higher mean PDC for tobramycin and were twice as likely to be adherent to tobramycin (PDC ≥ 80). In addition, program patients had fewer ER visits and lower ER insurance costs than matched control patients, and annual ER insurance costs were 34% lower for the CC-CF patients compared to controls. Future studies should examine what components of such programs are most effective to improve adherence and related outcomes.
| Practical implications
Patient-focused, pharmacy-based clinical management programs may increase adherence to CF medication therapy when implemented as part of a comprehensive pharmacy service for specialty medications.
Monthly refill reminders as well as screening for and counseling/ management of patient-reported adherence barriers may contribute toward higher medication adherence. This increased patient adherence should result in less utilization of the healthcare system for ER visits or hospitalizations.
| INFORMED CONSENT AND PATIENT DETAILS

